Strong Fourth Quarter Revenue
Repligen achieved a fourth quarter revenue of $167.5 million and full year revenue of $634.4 million, despite a $3.5 million exchange rate headwind, with a 13% revenue growth ex-COVID in Q4 versus the previous year.
CDMO and Equipment Segment Growth
Significant improvement in the CDMO business with sales and orders up high double digits sequentially. Equipment sales and orders also up more than 30% sequentially, contributing to overall growth.
Filtration and Analytics Performance
Filtration revenue and orders were strong, with the filtration franchise growing 14% for the full year. Analytics had a record quarter, with an 11% sequential and 8% year-over-year sales increase.
Strategic Priorities Achieved
Repligen executed on strategic priorities, including increasing the high probability funnel by 16% and launching innovative products like the KrosFlow RS 10 RPM system and AVIPure double-stranded RNA resin.
2025 Financial Guidance
Repligen projects 2025 revenue growth of 8% to 12% on a reported basis, with potential foreign exchange headwinds, aiming for low double-digit growth excluding COVID.